Search results (578)
« Back to PublicationsEconomic evaluation of alternative hepatitis C treatment options: a post hoc analysis of the VIETNARMS trial.
Journal article
Turner HC. et al, (2026), EClinicalMedicine, 95
Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B.
Journal article
Kalafateli M. et al, (2026), Clin Gastroenterol Hepatol, 24, 701 - 712.e8
ACE2 inhibition ELISA is an effective surrogate for SARS-CoV-2 live virus neutralisation.
Journal article
Tipton T. et al, (2026), Vaccine, 72
Response to Comments on 'Hepatitis B Virus (HBV) Treatment Eligibility in the UK: Retrospective Longitudinal Cohort Data to Explore the Impact of Changes in Clinical Guidelines'.
Journal article
Campbell C. et al, (2026), J Viral Hepat, 33
Association between COVID-19 vaccine immunogenicity and protection against infection and severe disease in clinically vulnerable patient populations: a systematic review and meta-analysis of observational studies.
Journal article
Danysz M. et al, (2026), Clin Microbiol Infect, 32, 41 - 55
Characterisation of People Living With Chronic Hepatitis B Virus Infection in England and Stratification by HBsAg Levels: A Cross-Sectional Study.
Journal article
Drysdale M. et al, (2025), J Viral Hepat, 32
HCV response-guided therapy: is shorter always better? - Authors' reply.
Journal article
Cooke GS. et al, (2025), Lancet, 406
Dynamic impact of bivalent COVID-19 vaccine boosters on systemic and mucosal antibody and T cell immunity.
Journal article
Kronsteiner B. et al, (2025), Sci Rep, 15
The development of a pan-genotypic T cell vaccine against hepatitis C virus using heterologous prime-boost strategies.
Journal article
Strain R. et al, (2025), Hepatology
Hepatitis B Virus (HBV) Treatment Eligibility in the UK: Retrospective Longitudinal Cohort Data to Explore the Impact of Changes in Clinical Guidelines.
Journal article
Campbell C. et al, (2025), J Viral Hepat, 32
Interplay of host and viral genetic variations in modulating antibody responses to genotype 3a hepatitis C virus: Implications for vaccine design.
Journal article
Wang Z. et al, (2025), Cell Rep, 44
Genome-wide association and gene-virus interaction study of liver disease in hepatitis C virus-infected patients
Preprint
Quistrebert J. et al, (2025)
Evaluation of Hepatitis B core-related antigen (HBcrAg) as a biomarker in cohorts from the United Kingdom and South Africa.
Journal article
Downs LO. et al, (2025), J Infect, 91
Dosing interval is a major factor determining the quality of T cells induced by SARS-CoV-2 mRNA and adenoviral vector vaccines.
Journal article
Murray SM. et al, (2025), Sci Immunol, 10
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.
Journal article
Amini A. et al, (2025), Sci Immunol, 10